Advertisement

TREATMENT OF REFRACTORY OR UNEXPLAINED CHRONIC COUGH WITH GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, OVER 52 WEEKS IN TWO PHASE III CLINICAL TRIALS

      TOPIC: Respiratory Care
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect